Sunday, March 31, 2019
The second of four student presentation this coming week in my Marijuana Law, Policy & Reform seminar will focus on federal scheduling under the Controlled Substances Act and the research and market realities impacted by the placement of marijuana in Schedule I. Here is how my student has summarized his topic, along with the background readings he has provided:
The placement of cannabis in Schedule I practically prevents comprehensive and meaningful research into its medical applications and potential harms. The federal government cites cannabis' placement in Schedule I as the reason rigorous research must be conducted before it can be rescheduled, but places restrictions on its research, because of its schedule, that are nearly impossible to overcome. Is there an alternative pathway to federal cannabis legalization, or at least rescheduling, so that more meaningful research can be conducted?
My presentation will examine U.S. drug scheduling, looking at the criteria and examples of substances in each schedule. I will then provide an overview of the FDA research model by which new drugs come to market, contrast it with the type of research conducted on cannabis, and discuss why meaningful, rigorous research into cannabis is so difficult. With this background, I will discuss the findings of a former UK drug-policy adviser that suggests substantial rescheduling is necessary, and how these findings helped initiate research into other Schedule I drugs. Finally, I will provide an overview of research into other Schedule I substances, particularly psychedelics, and how this research may accelerate the rescheduling or federal legalization of cannabis so that its impact on health may be studied more effectively.